Sandostatine LP

Phase 2Small molecule

AAssistance Publique - Hôpitaux de Paris

Sandostatine LP is one of 11 small molecule programs targeting Hyperinsulinism. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HyperinsulinismActive, not recruiting

HyperinsulinismPhase 2

Active, not recruiting

Competition

Competitive Landscape

13 competitors in Hyperinsulinism

#DrugCompanyPhaseTrials

Lanreotide PRF

Ipsen

Approved

1 2

Zegalogue

Zealand Pharma

Phase 3

2 3

Glucagon

XXeris Pharmaceuticals

Phase 2

1 4

Exendin-(9-39)

EEiger BioPharmaceuticals

Phase 2

1 5

Ersodetug

RRezolute

Phase 3

1 6

Rapamune

PPrism Pharmaceuticals

Phase 1

1 7

Fluorodopa F 18

MMayo Clinic

Phase 1

1 8

Sandostatine LP

AAssistance Publique - Hôpitaux de Paris

Phase 2

1 9

HM15136

Hanmi Pharmaceutical Company Limited

Phase 2

1 10

Insulin-Like Growth Factor I

CChildren's Hospital of Philadelphia

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Hyperinsulinism1 trial

Sandostatine® LP and Hyperinsulinism

Completed·AAssistance Publique - Hôpitaux de Paris·Phase 2·NCT00987168·10 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Sandostatine LP. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Sandostatine LP compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Sandostatine LP. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Assistance Publique - Hôpitaux de Paris company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: AAssistance Publique - Hôpitaux de Paris

Sandostatine LP

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Hyperinsulinism1 trial

References

Drug Info

Quick Facts

Related News